Wave Life Sciences names Monika Vnuk as chief business officer

Wave Life Sciences Ltd. (Nasdaq: WVE) announced the appointment of Monika Vnuk, MD, as Chief Business Officer, according to a company statement. Dr. Vnuk will join the executive team and lead business development, corporate development, and alliance management.

Dr. Vnuk previously served as Senior Vice President and Global Head of Partnering and Business Development at Sanofi, where she led global licensing, equity investments, and alliances. Before that, she was Managing Director at Blackstone Life Sciences, focused on late-stage product financing transactions.

Dr. Vnuk spent more than a decade at Pfizer in senior business development roles, including Vice President of R&D Business Development, where she led negotiations for the company's partnership with BioNTech on the co-development and distribution of COVID-19 vaccines. Earlier in her career, she worked in investment banking at Bank of America and at the venture capital firm Oxford Bioscience Partners. She holds an M.D. from Boston University School of Medicine and a B.A. in Mathematics and Philosophy from Boston University.

In connection with her appointment, Dr. Vnuk received a stock option to purchase 375,000 shares of Wave common stock, granted on September 21, 2026, at an exercise price of $4.25 per share. The grant was approved by Wave's Compensation Committee as an inducement under Nasdaq Stock Market Listing Rule 5635(c)(4). The option vests over four years, with 25% vesting on September 21, 2027, and the remainder vesting in equal quarterly installments over the following three years.

You May Also Be Interested In

• Bank of America adds two former CEOs to its board
• Nebius secures $3.5B credit facility from Citi for data centers
• HSBC Starts DTE Energy (DTE) at Hold